Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ceryvyn TherapeuticsASX:CYV 3-Year EPS without NRI Growth Rate is 14.00% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 1,162 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 53.18% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 14.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -37.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -31.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ceryvyn Therapeutics was 27.50% per year. The lowest was -117.20% per year. And the median was -18.20% per year.
Ceryvyn Therapeutics (ASX:CYV) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ceryvyn Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ASX:CYV vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Ceryvyn Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 14.00% mean?
Ceryvyn Therapeutics (ASX:CYV) has a 3-Year EPS without NRI Growth Rate of 14.00% as of Jun. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #618 out of 1162 companies in the Biotechnology industry, placing it in the top 53.2%.
Is Ceryvyn Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Ceryvyn Therapeutics' current 3-Year EPS without NRI Growth Rate is 14.00%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Ceryvyn Therapeutics' value of 14.00% is 13.6% below this industry median. Based on the distribution chart, Ceryvyn Therapeutics ranks #618 out of 1162 companies in the Biotechnology industry, which is below the industry midpoint.
How does Ceryvyn Therapeutics' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #618 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Ceryvyn Therapeutics' value of 14.00% is 13.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ceryvyn Therapeutics's current 3-Year EPS without NRI Growth Rate of 14.00% is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current 3-Year EPS without NRI Growth Rate is 14.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current 3-Year EPS without NRI Growth Rate of 14.00%. The current 3-Year EPS without NRI Growth Rate is 14.00% and 13.6% below the Biotechnology industry median of 16.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current 3-Year EPS without NRI Growth Rate is 14.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYV has been successfully added to your 
